Makers Laboratories Ltd

Makers Laboratories Ltd: Trading window closed from 1 October 2026 until 48 hours after the declaration of the unaudited financial results for the 2nd quarter and half year ended 30 September 2026 (FY 2026-27).

Director appointment via postal ballot

• Purpose: Postal ballot to approve appointment/continuation of Saahil Parikh as NED.
• Resolution: Ordinary, appointment/continuation of Saahil Parikh as Non-Executive, Non-Independent Director liable to rotate.
• Term: From 11 August 2026.
• Experience: 25 years in pharma; former Whole-time Director/CEO (2011–2026).
• Independence: Non-Independent.
• Cut-off date: 11 September 2026; remote e-voting: 17 September to 16 October 2026.
• Facility: e-voting managed by NSDL.

Rating Details

• Instrument/Facility: Long Term Bank Facilities; Amount Rs 8.00 crore.
• Rating: CARE BBB+; Outlook: Stable.
• Action: Reaffirmed.
• Rating Agency: CARE Edge Ratings.

AGM Details

• Date and time: 7 August 2026 at 12:30 p.m. IST.
• Mode: VC/OAVM.
• Cut-off date for voting: 31 July 2026.
• Shareholders on record: 3821.
• AGM attendees via VC: 41.

Key Resolutions & Outcomes

• Resolution 1: Adoption of audited financial statements and consolidated statements.
• Resolution 2: Re-appointment of Saahil Parikh by rotation.
• Resolution 3: Approval of related party contracts with Ipca Laboratories Limited.
• Resolution 4: Ratification of remuneration to Cost Auditors for FY 2026-27.

Voting Results by Resolution

• Resolution 1: In favour 99.99%, against 0.01% (51 in favour, 2 against).
• Resolution 2: In favour 99.99%, against 0.01% (50 in favour, 3 against).
• Resolution 3: In favour 99.63%, against 0.37% (38 in favour, 3 against).
• Resolution 4: In favour 99.99%, against 0.01% (51 in favour, 2 against).

Director Changes

• Saahil Parikh retires by rotation; re-appointed as Director.

Auditors & Remuneration

• Cost Auditors remuneration ratified for FY 2026-27; Poddar & Co.

Related Party Transactions

• Approval of related party transactions with Ipca Laboratories Limited; nature: contracts/transactions; value not disclosed.

AGM details

• AGM held on 7 August 2026 at 12:30 p.m. via VC/OAVM.
• Remote e-voting from 3–6 August 2026; cut-off 31 July 2026.
• Meeting ended around 1:30 p.m.; Scrutinizer appointed for e-voting.

Key resolutions

• Ordinary: Adopt audited standalone and consolidated financial statements for year ended 31 March 2026.
• Ordinary: Re-appoint Saahil Parikh by rotation as Director.
• Special: Ordinary Resolution to approve related party transactions with Ipca Laboratories Ltd.
• Ordinary: Ratify remuneration of Rs. 1,50,000 to Poddar & Co. for FY 2026-27.

Voting status

• Results to be declared after scrutiny report; will be posted on the company's website.

Director changes

• Saahil Parikh re-appointed by rotation.

Material related party transactions

• Ipca Laboratories Ltd. identified as related party; nature: related party transactions.

Board changes & committee reconstitution

• Saahil Parikh's WTD/CEO term ends Aug 10, 2026; declines reappointment.
• He will be Non-Executive, Non-Independent Director from Aug 11, 2026, subject to shareholders' approval.
• Board committees reconstituted: Stakeholders Relationship Committee chaired by Verma; Saahil Parikh appointed member.
• Risk Management Committee includes Saahil Parikh (Director), Nilesh Jain (Executive WTD), Sandeep Kadam (CFO).
• Board meeting held Aug 7, 2026; duration 11:00–11:55 AM.

Standalone results

• Standalone revenue from operations: 1,018.75 lacs; total income: 1,025.90 lacs.
• Total expenses: 1,151.62 lacs; PBT before tax: -125.72 lacs; PAT: -107.50 lacs.
• EPS (basic/diluted): -1.82; paid-up capital: 590.04 lacs.
• Single reportable segment: Pharmaceuticals; auditor's limited review unmodified.

Consolidated results

• Consolidated revenue from operations: 4,277.16 lacs; total income: 4,338.09 lacs.
• Total expenses: 3,708.60 lacs; PBT: 629.49 lacs; tax: 169.85 lacs; PAT: 459.64 lacs.
• Non-controlling interests: 309.21 lacs; PAT to owners: 150.43 lacs; consolidated EPS: 1.85.
• Segments: Pharmaceutical and Chemical Manufacturing; Resonance Specialties Limited is a subsidiary.

Segment details & notes

• Pharma revenue: 1,025.90 lacs; Chemical revenue: 3,312.19 lacs; Q2 PBT Pharma: -125.74; Chemical: 755.23.
• Group has two reportable segments: Pharmaceuticals and Chemical Manufacturing.
• Auditors note: Resonance Specialties Limited interim results not reviewed; overall result not modified for this.

AGM notice and related compliance

• 41st AGM scheduled for 7 August 2026 at 12:30 PM via VC/OAVM.
• Annual Report 2025-26 accessible online at makerslabs.com.
• Letters issued to shareholders without registered email addresses.
• Cut-off date for non-registered email holders: 3 July 2026.
• KYC updation and physical dematerialisation urged per SEBI circular.
• Electronic payments allowed for physical folios missing PAN per SEBI policy.
• Registrar MUFG Intime India Private Limited (formerly Link Intime) handles updates.
• Queries to be raised through registrar's service portal.